ID   HPGDS_HUMAN             Reviewed;         199 AA.
AC   O60760; Q6FHT9;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   10-MAY-2017, entry version 163.
DE   RecName: Full=Hematopoietic prostaglandin D synthase;
DE            Short=H-PGDS;
DE            EC=5.3.99.2 {ECO:0000269|PubMed:10824118, ECO:0000269|PubMed:11672424, ECO:0000269|PubMed:12627223, ECO:0000269|PubMed:16547010, ECO:0000269|PubMed:19939518, ECO:0000269|PubMed:9353279, ECO:0000269|PubMed:9425264};
DE   AltName: Full=GST class-sigma;
DE   AltName: Full=Glutathione S-transferase;
DE            EC=2.5.1.18 {ECO:0000269|PubMed:10824118, ECO:0000269|PubMed:11672424, ECO:0000269|PubMed:15113825};
DE   AltName: Full=Glutathione-dependent PGD synthase;
DE   AltName: Full=Glutathione-requiring prostaglandin D synthase;
DE   AltName: Full=Prostaglandin-H2 D-isomerase;
GN   Name=HPGDS; Synonyms=GSTS, PGDS, PTGDS2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], FUNCTION, CATALYTIC
RP   ACTIVITY, COFACTOR, AND TISSUE SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=10824118; DOI=10.1046/j.1432-1327.2000.01362.x;
RA   Kanaoka Y., Fujimori K., Kikuno R., Sakaguchi Y., Urade Y.,
RA   Hayaishi O.;
RT   "Structure and chromosomal localization of human and mouse genes for
RT   hematopoietic prostaglandin D synthase.";
RL   Eur. J. Biochem. 267:3315-3322(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, COFACTOR,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND TISSUE SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=11672424; DOI=10.1042/0264-6021:3590507;
RA   Jowsey I.R., Thomson A.M., Flanagan J.U., Murdock P.R., Moore G.B.,
RA   Meyer D.J., Murphy G.J., Smith S.A., Hayes J.D.;
RT   "Mammalian class Sigma glutathione S-transferases: catalytic
RT   properties and tissue-specific expression of human and rat GSH-
RT   dependent prostaglandin D2 synthases.";
RL   Biochem. J. 359:507-516(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Substantia nigra;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, TISSUE SPECIFICITY,
RP   DEVELOPMENTAL STAGE, AND INDUCTION.
RC   TISSUE=Megakaryocyte;
RX   PubMed=9425264; DOI=10.1006/bbrc.1997.7803;
RA   Suzuki T., Watanabe K., Kanaoka Y., Sato T., Hayaishi O.;
RT   "Induction of hematopoietic prostaglandin D synthase in human
RT   megakaryocytic cells by phorbol ester.";
RL   Biochem. Biophys. Res. Commun. 241:288-293(1997).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Megakaryocyte;
RX   PubMed=9353279; DOI=10.1074/jbc.272.45.28263;
RA   Mahmud I., Ueda N., Yamaguchi H., Yamashita R., Yamamoto S.,
RA   Kanaoka Y., Urade Y., Hayaishi O.;
RT   "Prostaglandin D synthase in human megakaryoblastic cells.";
RL   J. Biol. Chem. 272:28263-28266(1997).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) IN COMPLEXES WITH CALCIUM IONS;
RP   MAGNESIUM IONS AND GLUTATHIONE, FUNCTION, CATALYTIC ACTIVITY, ENZYME
RP   REGULATION, SUBUNIT, BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF
RP   ASP-93; ASP-96 AND ASP-97.
RX   PubMed=12627223; DOI=10.1038/nsb907;
RA   Inoue T., Irikura D., Okazaki N., Kinugasa S., Matsumura H.,
RA   Uodome N., Yamamoto M., Kumasaka T., Miyano M., Kai Y., Urade Y.;
RT   "Mechanism of metal activation of human hematopoietic prostaglandin D
RT   synthase.";
RL   Nat. Struct. Biol. 10:291-296(2003).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) IN COMPLEX WITH GLUTATHIONE;
RP   MAGNESIUM IONS AND THE SYNTHETIC INHIBITOR BSBT, FUNCTION, SUBUNIT,
RP   CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=15113825; DOI=10.1093/jb/mvh033;
RA   Inoue T., Okano Y., Kado Y., Aritake K., Irikura D., Uodome N.,
RA   Okazaki N., Kinugasa S., Shishitani H., Matsumura H., Kai Y.,
RA   Urade Y.;
RT   "First determination of the inhibitor complex structure of human
RT   hematopoietic prostaglandin D synthase.";
RL   J. Biochem. 135:279-283(2004).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) IN COMPLEX WITH GLUTATHIONE;
RP   MAGNESIUM IONS AND THE SYNTHETIC INHIBITOR HQL-79, FUNCTION, AND
RP   CATALYTIC ACTIVITY.
RX   PubMed=16547010; DOI=10.1074/jbc.M506431200;
RA   Aritake K., Kado Y., Inoue T., Miyano M., Urade Y.;
RT   "Structural and functional characterization of HQL-79, an orally
RT   selective inhibitor of human hematopoietic prostaglandin D synthase.";
RL   J. Biol. Chem. 281:15277-15286(2006).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) IN COMPLEXES WITH GLUTATHIONE
RP   AND SYNTHETIC INHIBITORS, AND SUBUNIT.
RX   PubMed=18341273; DOI=10.1021/jm701509k;
RA   Hohwy M., Spadola L., Lundquist B., Hawtin P., Dahmen J.,
RA   Groth-Clausen I., Nilsson E., Persdotter S., von Wachenfeldt K.,
RA   Folmer R.H., Edman K.;
RT   "Novel prostaglandin D synthase inhibitors generated by fragment-based
RT   drug design.";
RL   J. Med. Chem. 51:2178-2186(2008).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.91 ANGSTROMS) IN COMPLEX WITH GLUTATHIONE AND
RP   SYNTHETIC INHIBITOR, CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=19939518; DOI=10.1016/j.ejmech.2009.10.025;
RA   Weber J.E., Oakley A.J., Christ A.N., Clark A.G., Hayes J.D., Hall R.,
RA   Hume D.A., Board P.G., Smythe M.L., Flanagan J.U.;
RT   "Identification and characterisation of new inhibitors for the human
RT   hematopoietic prostaglandin D2 synthase.";
RL   Eur. J. Med. Chem. 45:447-454(2010).
CC   -!- FUNCTION: Bifunctional enzyme which catalyzes both the conversion
CC       of PGH2 to PGD2, a prostaglandin involved in smooth muscle
CC       contraction/relaxation and a potent inhibitor of platelet
CC       aggregation, and the conjugation of glutathione with a wide range
CC       of aryl halides and organic isothiocyanates. Also exhibits low
CC       glutathione-peroxidase activity towards cumene hydroperoxide.
CC       {ECO:0000269|PubMed:10824118, ECO:0000269|PubMed:11672424,
CC       ECO:0000269|PubMed:12627223, ECO:0000269|PubMed:15113825,
CC       ECO:0000269|PubMed:16547010, ECO:0000269|PubMed:19939518,
CC       ECO:0000269|PubMed:9353279, ECO:0000269|PubMed:9425264}.
CC   -!- CATALYTIC ACTIVITY: (5Z,13E,15S)-9-alpha,11-alpha-epidioxy-15-
CC       hydroxyprosta-5,13-dienoate = (5Z,13E,15S)-9-alpha,15-dihydroxy-
CC       11-oxoprosta-5,13-dienoate. {ECO:0000269|PubMed:10824118,
CC       ECO:0000269|PubMed:11672424, ECO:0000269|PubMed:12627223,
CC       ECO:0000269|PubMed:16547010, ECO:0000269|PubMed:19939518,
CC       ECO:0000269|PubMed:9353279, ECO:0000269|PubMed:9425264}.
CC   -!- CATALYTIC ACTIVITY: RX + glutathione = HX + R-S-glutathione.
CC       {ECO:0000269|PubMed:10824118, ECO:0000269|PubMed:11672424,
CC       ECO:0000269|PubMed:15113825}.
CC   -!- COFACTOR:
CC       Name=glutathione; Xref=ChEBI:CHEBI:57925;
CC         Evidence={ECO:0000269|PubMed:10824118,
CC         ECO:0000269|PubMed:11672424, ECO:0000269|PubMed:9353279,
CC         ECO:0000269|PubMed:9425264};
CC       Note=Glutathione is required for the prostaglandin D synthase
CC       activity. {ECO:0000269|PubMed:10824118,
CC       ECO:0000269|PubMed:11672424, ECO:0000269|PubMed:9353279,
CC       ECO:0000269|PubMed:9425264};
CC   -!- ENZYME REGULATION: Prostaglandin PGD2 synthesis is stimulated by
CC       calcium and magnesium ions. One calcium or magnesium ion is bound
CC       between the subunits of the homodimer. The interactions with the
CC       protein are for the most part mediated via water molecules.
CC       Magnesium increases the affinity for glutathione, while calcium
CC       has no effect on the affinity for glutathione.
CC       {ECO:0000269|PubMed:12627223}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=8 mM for glutathione for the glutathione-conjugating activity
CC         {ECO:0000269|PubMed:11672424, ECO:0000269|PubMed:12627223,
CC         ECO:0000269|PubMed:15113825};
CC         KM=0.6 mM for glutathione for the prostaglandin D synthase
CC         activity in the presence of EDTA {ECO:0000269|PubMed:11672424,
CC         ECO:0000269|PubMed:12627223, ECO:0000269|PubMed:15113825};
CC         KM=0.14 mM for glutathione for the prostaglandin D synthase
CC         activity in the presence of magnesium ions
CC         {ECO:0000269|PubMed:11672424, ECO:0000269|PubMed:12627223,
CC         ECO:0000269|PubMed:15113825};
CC         Vmax=8.6 umol/min/mg enzyme with 1-bromo-2,4-dinitrobenzene as
CC         substrate {ECO:0000269|PubMed:11672424,
CC         ECO:0000269|PubMed:12627223, ECO:0000269|PubMed:15113825};
CC         Vmax=5.1 umol/min/mg enzyme with 1-chloro-2,4-dinitrobenzene as
CC         substrate {ECO:0000269|PubMed:11672424,
CC         ECO:0000269|PubMed:12627223, ECO:0000269|PubMed:15113825};
CC         Vmax=44.3 umol/min/mg enzyme with 1-fluoro-2,4-dinitrobenzene as
CC         substrate {ECO:0000269|PubMed:11672424,
CC         ECO:0000269|PubMed:12627223, ECO:0000269|PubMed:15113825};
CC         Vmax=10.7 umol/min/mg enzyme with 1-iodo-2,4-dinitrobenzene as
CC         substrate {ECO:0000269|PubMed:11672424,
CC         ECO:0000269|PubMed:12627223, ECO:0000269|PubMed:15113825};
CC         Vmax=6.8 umol/min/mg enzyme with allyl isothiocyanate as
CC         substrate {ECO:0000269|PubMed:11672424,
CC         ECO:0000269|PubMed:12627223, ECO:0000269|PubMed:15113825};
CC         Vmax=6.3 umol/min/mg enzyme with benzyl isothiocyanate as
CC         substrate {ECO:0000269|PubMed:11672424,
CC         ECO:0000269|PubMed:12627223, ECO:0000269|PubMed:15113825};
CC         Vmax=0.05 umol/min/mg enzyme with cumene hydroperoxide as
CC         substrate {ECO:0000269|PubMed:11672424,
CC         ECO:0000269|PubMed:12627223, ECO:0000269|PubMed:15113825};
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:12627223,
CC       ECO:0000269|PubMed:15113825, ECO:0000269|PubMed:16547010,
CC       ECO:0000269|PubMed:18341273, ECO:0000269|PubMed:19939518}.
CC   -!- INTERACTION:
CC       Q96GS6:ABHD17A; NbExp=3; IntAct=EBI-10187349, EBI-2870273;
CC       Q96B67:ARRDC3; NbExp=7; IntAct=EBI-10187349, EBI-2875665;
CC       P08582-2:MELTF; NbExp=3; IntAct=EBI-10187349, EBI-10195914;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:9353279}.
CC   -!- TISSUE SPECIFICITY: Expressed in a number of megakaryocytic cell
CC       lines but not in platelets. Highly expressed in adipose tissue,
CC       macrophages and placenta. Also expressed at lower levels in lung,
CC       heart, lymph nodes, appendix, bone marrow and fetal liver.
CC       {ECO:0000269|PubMed:10824118, ECO:0000269|PubMed:11672424,
CC       ECO:0000269|PubMed:9353279, ECO:0000269|PubMed:9425264}.
CC   -!- DEVELOPMENTAL STAGE: Highest levels in immature megakaryocytic
CC       cells. Disappears after final differentiation to platelets.
CC       {ECO:0000269|PubMed:9425264}.
CC   -!- INDUCTION: By 12-O-tetradecanoylphorbol-13-acetate (TPA).
CC       {ECO:0000269|PubMed:9425264}.
CC   -!- SIMILARITY: Belongs to the GST superfamily. Sigma family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D82073; BAA25545.1; -; mRNA.
DR   EMBL; AB008830; BAA96854.1; -; Genomic_DNA.
DR   EMBL; AK290075; BAF82764.1; -; mRNA.
DR   EMBL; CR541662; CAG46463.1; -; mRNA.
DR   EMBL; CR541679; CAG46480.1; -; mRNA.
DR   EMBL; CH471057; EAX06052.1; -; Genomic_DNA.
DR   EMBL; BC020734; AAH20734.1; -; mRNA.
DR   CCDS; CCDS3640.1; -.
DR   RefSeq; NP_055300.1; NM_014485.2.
DR   UniGene; Hs.128433; -.
DR   PDB; 1IYH; X-ray; 1.70 A; A/B/C/D=2-199.
DR   PDB; 1IYI; X-ray; 1.80 A; A/B/C/D=2-199.
DR   PDB; 1V40; X-ray; 1.90 A; A/B/C/D=2-199.
DR   PDB; 2CVD; X-ray; 1.45 A; A/B/C/D=2-199.
DR   PDB; 2VCQ; X-ray; 1.95 A; A/B/C/D=1-199.
DR   PDB; 2VCW; X-ray; 1.95 A; A/B/C/D=1-199.
DR   PDB; 2VCX; X-ray; 2.10 A; A/B/C/D=1-199.
DR   PDB; 2VCZ; X-ray; 1.95 A; A/B/C/D=1-199.
DR   PDB; 2VD0; X-ray; 2.20 A; A/B/C/D=1-199.
DR   PDB; 2VD1; X-ray; 2.25 A; A/B/C/D=1-199.
DR   PDB; 3EE2; X-ray; 1.91 A; A/B=1-199.
DR   PDB; 3KXO; X-ray; 2.10 A; A/B=1-199.
DR   PDB; 3VI5; X-ray; 2.00 A; A/B/C/D=2-199.
DR   PDB; 3VI7; X-ray; 2.00 A; A/B/C/D=2-199.
DR   PDB; 4EC0; X-ray; 1.85 A; A/B=1-199.
DR   PDB; 4EDY; X-ray; 1.72 A; A/B=2-199.
DR   PDB; 4EDZ; X-ray; 2.00 A; A/B/C/D=2-199.
DR   PDB; 4EE0; X-ray; 1.75 A; A/B=2-199.
DR   PDB; 5AIS; X-ray; 1.85 A; A/B/C/D=2-199.
DR   PDB; 5AIV; X-ray; 2.04 A; A/B/C/D=2-199.
DR   PDB; 5AIX; X-ray; 2.10 A; A/B/C/D=2-199.
DR   PDBsum; 1IYH; -.
DR   PDBsum; 1IYI; -.
DR   PDBsum; 1V40; -.
DR   PDBsum; 2CVD; -.
DR   PDBsum; 2VCQ; -.
DR   PDBsum; 2VCW; -.
DR   PDBsum; 2VCX; -.
DR   PDBsum; 2VCZ; -.
DR   PDBsum; 2VD0; -.
DR   PDBsum; 2VD1; -.
DR   PDBsum; 3EE2; -.
DR   PDBsum; 3KXO; -.
DR   PDBsum; 3VI5; -.
DR   PDBsum; 3VI7; -.
DR   PDBsum; 4EC0; -.
DR   PDBsum; 4EDY; -.
DR   PDBsum; 4EDZ; -.
DR   PDBsum; 4EE0; -.
DR   PDBsum; 5AIS; -.
DR   PDBsum; 5AIV; -.
DR   PDBsum; 5AIX; -.
DR   ProteinModelPortal; O60760; -.
DR   SMR; O60760; -.
DR   BioGrid; 118128; 4.
DR   IntAct; O60760; 6.
DR   STRING; 9606.ENSP00000295256; -.
DR   BindingDB; O60760; -.
DR   ChEMBL; CHEMBL5879; -.
DR   DrugBank; DB08790; 1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID.
DR   DrugBank; DB01897; 2-(2f-Benzothiazolyl)-5-Styryl-3-(4f-Phthalhydrazidyl)Tetrazolium Chloride.
DR   DrugBank; DB08695; 3-(4-nitrophenyl)-1H-pyrazole.
DR   DrugBank; DB07613; 3-phenyl-5-(1H-pyrazol-3-yl)isoxazole.
DR   DrugBank; DB07917; 4-(BENZHYDRYLOXY)-1-[3-(1H-TETRAAZOL-5-YL)PROPYL]PIPERIDINE.
DR   DrugBank; DB00143; Glutathione.
DR   DrugBank; DB04077; Glycerol.
DR   DrugBank; DB08313; nocodazole.
DR   DrugBank; DB07615; Tranilast.
DR   GuidetoPHARMACOLOGY; 1381; -.
DR   SwissLipids; SLP:000000828; -.
DR   PhosphoSitePlus; O60760; -.
DR   BioMuta; HPGDS; -.
DR   PaxDb; O60760; -.
DR   PeptideAtlas; O60760; -.
DR   PRIDE; O60760; -.
DR   Ensembl; ENST00000295256; ENSP00000295256; ENSG00000163106.
DR   GeneID; 27306; -.
DR   KEGG; hsa:27306; -.
DR   UCSC; uc003hte.2; human.
DR   CTD; 27306; -.
DR   DisGeNET; 27306; -.
DR   GeneCards; HPGDS; -.
DR   HGNC; HGNC:17890; HPGDS.
DR   HPA; HPA024035; -.
DR   MIM; 602598; gene.
DR   neXtProt; NX_O60760; -.
DR   OpenTargets; ENSG00000163106; -.
DR   PharmGKB; PA165664133; -.
DR   eggNOG; KOG1695; Eukaryota.
DR   eggNOG; ENOG4111VAU; LUCA.
DR   GeneTree; ENSGT00670000097856; -.
DR   HOGENOM; HOG000115733; -.
DR   HOVERGEN; HBG105321; -.
DR   InParanoid; O60760; -.
DR   KO; K04097; -.
DR   OMA; YLGENEW; -.
DR   OrthoDB; EOG091G0MBB; -.
DR   PhylomeDB; O60760; -.
DR   TreeFam; TF105321; -.
DR   BioCyc; MetaCyc:HS08788-MONOMER; -.
DR   BRENDA; 2.5.1.18; 2681.
DR   BRENDA; 5.3.99.2; 2681.
DR   Reactome; R-HSA-156590; Glutathione conjugation.
DR   Reactome; R-HSA-2162123; Synthesis of Prostaglandins (PG) and Thromboxanes (TX).
DR   SABIO-RK; O60760; -.
DR   EvolutionaryTrace; O60760; -.
DR   GeneWiki; PGDS; -.
DR   GenomeRNAi; 27306; -.
DR   PRO; PR:O60760; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000163106; -.
DR   Genevisible; O60760; HS.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0004364; F:glutathione transferase activity; TAS:Reactome.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0004667; F:prostaglandin-D synthase activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0019371; P:cyclooxygenase pathway; TAS:Reactome.
DR   GO; GO:1901687; P:glutathione derivative biosynthetic process; TAS:Reactome.
DR   GO; GO:0007626; P:locomotory behavior; TAS:ProtInc.
DR   GO; GO:2000255; P:negative regulation of male germ cell proliferation; IEA:Ensembl.
DR   GO; GO:0006693; P:prostaglandin metabolic process; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; NAS:ProtInc.
DR   InterPro; IPR010987; Glutathione-S-Trfase_C-like.
DR   InterPro; IPR004045; Glutathione_S-Trfase_N.
DR   InterPro; IPR004046; GST_C.
DR   InterPro; IPR012336; Thioredoxin-like_fold.
DR   Pfam; PF14497; GST_C_3; 1.
DR   Pfam; PF02798; GST_N; 1.
DR   SUPFAM; SSF47616; SSF47616; 1.
DR   SUPFAM; SSF52833; SSF52833; 1.
DR   PROSITE; PS50405; GST_CTER; 1.
DR   PROSITE; PS50404; GST_NTER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Complete proteome; Cytoplasm;
KW   Fatty acid biosynthesis; Fatty acid metabolism; Isomerase;
KW   Lipid biosynthesis; Lipid metabolism; Magnesium; Metal-binding;
KW   Prostaglandin biosynthesis; Prostaglandin metabolism;
KW   Reference proteome; Transferase.
FT   CHAIN         1    199       Hematopoietic prostaglandin D synthase.
FT                                /FTId=PRO_0000185934.
FT   DOMAIN        2     79       GST N-terminal.
FT   DOMAIN       81    199       GST C-terminal.
FT   REGION       49     51       Glutathione binding.
FT                                {ECO:0000269|PubMed:12627223,
FT                                ECO:0000269|PubMed:15113825,
FT                                ECO:0000269|PubMed:16547010,
FT                                ECO:0000269|PubMed:18341273,
FT                                ECO:0000269|PubMed:19939518}.
FT   REGION       63     64       Glutathione binding.
FT                                {ECO:0000269|PubMed:12627223,
FT                                ECO:0000269|PubMed:15113825,
FT                                ECO:0000269|PubMed:16547010,
FT                                ECO:0000269|PubMed:18341273,
FT                                ECO:0000269|PubMed:19939518}.
FT   BINDING       8      8       Glutathione.
FT                                {ECO:0000269|PubMed:12627223,
FT                                ECO:0000269|PubMed:15113825,
FT                                ECO:0000269|PubMed:16547010,
FT                                ECO:0000269|PubMed:18341273,
FT                                ECO:0000269|PubMed:19939518}.
FT   BINDING      14     14       Glutathione.
FT                                {ECO:0000269|PubMed:12627223,
FT                                ECO:0000269|PubMed:15113825,
FT                                ECO:0000269|PubMed:16547010,
FT                                ECO:0000269|PubMed:18341273,
FT                                ECO:0000269|PubMed:19939518}.
FT   BINDING      39     39       Glutathione.
FT                                {ECO:0000269|PubMed:12627223,
FT                                ECO:0000269|PubMed:15113825,
FT                                ECO:0000269|PubMed:16547010,
FT                                ECO:0000269|PubMed:18341273,
FT                                ECO:0000269|PubMed:19939518}.
FT   MUTAGEN      93     93       D->N: Loss of activation by calcium or
FT                                magnesium ions.
FT                                {ECO:0000269|PubMed:12627223}.
FT   MUTAGEN      96     96       D->N: Increases PGD2 synthesis. Loss of
FT                                activation by calcium or magnesium ions.
FT                                {ECO:0000269|PubMed:12627223}.
FT   MUTAGEN      97     97       D->N: Reduces PGD2 synthesis by 99%. Loss
FT                                of activation by calcium or magnesium
FT                                ions. {ECO:0000269|PubMed:12627223}.
FT   CONFLICT    187    187       V -> I (in Ref. 2; no nucleotide entry).
FT                                {ECO:0000305}.
FT   STRAND        4     12       {ECO:0000244|PDB:2CVD}.
FT   HELIX        13     15       {ECO:0000244|PDB:2CVD}.
FT   HELIX        16     24       {ECO:0000244|PDB:2CVD}.
FT   STRAND       30     34       {ECO:0000244|PDB:2CVD}.
FT   HELIX        36     38       {ECO:0000244|PDB:2CVD}.
FT   HELIX        39     43       {ECO:0000244|PDB:2CVD}.
FT   STRAND       46     49       {ECO:0000244|PDB:1IYH}.
FT   STRAND       53     56       {ECO:0000244|PDB:2CVD}.
FT   STRAND       59     62       {ECO:0000244|PDB:2CVD}.
FT   HELIX        64     72       {ECO:0000244|PDB:2CVD}.
FT   HELIX        76     78       {ECO:0000244|PDB:5AIS}.
FT   HELIX        82    100       {ECO:0000244|PDB:2CVD}.
FT   HELIX       109    121       {ECO:0000244|PDB:2CVD}.
FT   HELIX       123    135       {ECO:0000244|PDB:2CVD}.
FT   STRAND      139    142       {ECO:0000244|PDB:2CVD}.
FT   HELIX       148    163       {ECO:0000244|PDB:2CVD}.
FT   TURN        165    170       {ECO:0000244|PDB:2CVD}.
FT   HELIX       172    182       {ECO:0000244|PDB:2CVD}.
FT   HELIX       185    193       {ECO:0000244|PDB:2CVD}.
SQ   SEQUENCE   199 AA;  23344 MW;  A4ED2476B16CC5C3 CRC64;
     MPNYKLTYFN MRGRAEIIRY IFAYLDIQYE DHRIEQADWP EIKSTLPFGK IPILEVDGLT
     LHQSLAIARY LTKNTDLAGN TEMEQCHVDA IVDTLDDFMS CFPWAEKKQD VKEQMFNELL
     TYNAPHLMQD LDTYLGGREW LIGNSVTWAD FYWEICSTTL LVFKPDLLDN HPRLVTLRKK
     VQAIPAVANW IKRRPQTKL
//
